Updated Interpretation of the NCCN Clinical Practice Guidelines (Version 3. 2023)  for Non-small Cell Lung Cancer.

Author: Lingling ZHU ¹ ; Ting WANG ¹ ; Juan WU ² ; Xiaoqian ZHAI ¹ ; Qiang WU ¹ ; Hanyu DENG ¹ ; Changlong QIN ¹ ; Long TIAN ¹ ; Qinghua ZHOU ¹
Author Information

1. Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
2. Outpatient Department, West China Hospital, Sichuan University, Chengdu 610041, China.
Publication Type:Practice Guideline
Keywords: Clinical practice; Evidence-based medicine; Guideline interpretation; Lung neoplasms; NCCN guideline
MeSH: Humans; Carcinoma, Non-Small-Cell Lung; China; Lung Neoplasms; Thorax
From: Chinese Journal of Lung Cancer 2023;26(6):407-415
CountryChina
Language:Chinese
Abstract: Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Non-small cell lung cancer (NSCLC) is the main pathological subtype of lung cancer. On April 13, 2023, the National Comprehensive Cancer Network (NCCN) released the third edition of the 2023 NCCN Oncology Clinical Practice Guidelines: Non-small Cell Lung Cancer, which reflects the latest advances in international lung cancer research. This article will interpret the main updated contents of the new edition of the guidelines, and compare it with the third edition of the NCCN guidelines in 2022, so as to provide references about the diagnosis and treatment of NSCLC for clinical medical personnel in China. .